Zhejiang Wecome Pharmaceutical Company Limited (SHE:300878)
China flag China · Delayed Price · Currency is CNY
29.52
+0.92 (3.22%)
Nov 6, 2026, 11:05 AM CST

SHE:300878 Income Statement

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Operating Revenue
247.71220.68347.01514.56529.41631.18
Other Revenue
4.594.594.195.073.031.77
252.3225.27351.2519.62532.44632.95
Revenue Growth
91.62%-35.86%-32.41%-2.41%-15.88%1.64%
Cost of Revenue
165.22185.04223.4257.69219.08204.38
Gross Profit
87.0840.23127.8261.93313.36428.57
Selling, General & Admin
119.84147.61261.73249.42230.39294.74
Research & Development
6.899.3714.1942.839.3237.02
Other Operating Expenses
8.396.4810.231.07-17.94.8
Operating Expenses
145.86165.37289.32281.83259.12344.96
Operating Income
-58.78-125.14-161.53-19.954.2483.62
Interest Expense
-0.61-6.27-9.34-9.45-5.41-2.16
Interest & Investment Income
0.251.3694.2614.5617.045.55
Other Non Operating Income (Expenses)
-1.87-0.02-0.07-0.09-0.16-0.09
EBT Excluding Unusual Items
-61.02-130.08-76.67-14.8865.7186.91
Impairment of Goodwill
-10.97-10.97-7.76-0.14-0.22-0.08
Gain (Loss) on Sale of Investments
-12.51-12.48-4.56--
Gain (Loss) on Sale of Assets
-5-1.64-0.47-0.01-0.630.07
Asset Writedown
-37.81-54.46-76.26-0.52-0.18-0.02
Other Unusual Items
11.341.152.894.3-1.5213.16
Pretax Income
-115.97-208.48-158.28-6.6863.15100.03
Income Tax Expense
12.7621.26-13.40.4213.673.48
Earnings From Continuing Operations
-128.72-229.73-144.88-7.149.4896.55
Minority Interest in Earnings
2.162.39-2.55-1.85-0.67-0.05
Net Income
-126.57-227.34-147.43-8.9548.8196.5
Net Income to Common
-126.57-227.34-147.43-8.9548.8196.5
Net Income Growth
-----49.42%-28.95%
Shares Outstanding (Basic)
145145143149144144
Shares Outstanding (Diluted)
145145143149144144
Shares Change
1.15%1.17%-4.09%3.96%-0.32%19.60%
EPS (Basic)
-0.87-1.57-1.03-0.060.340.67
EPS (Diluted)
-0.87-1.57-1.03-0.060.340.67
EPS Growth
-----49.25%-40.59%

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Free Cash Flow
-58.05-0.08-154.1-81-28.21-238.84
Free Cash Flow Per Share
-0.40-0.00-1.08-0.54-0.20-1.66
Dividend Per Share
--0.1400.250-0.300
Dividend Growth
---44.00%---46.00%
Gross Margin
34.52%17.86%36.39%50.41%58.85%67.71%
Operating Margin
-23.30%-55.55%-45.99%-3.83%10.19%13.21%
Profit Margin
-50.17%-100.92%-41.98%-1.72%9.17%15.25%
Free Cash Flow Margin
-23.01%-0.04%-43.88%-15.59%-5.30%-37.73%
EBITDA
-4.23-64.79-93.4526.7584.0497.65
EBITDA Margin
-1.68%-28.76%-26.61%5.15%15.78%15.43%
D&A For EBITDA
54.5460.3468.0746.6529.814.03
EBIT
-58.78-125.14-161.53-19.954.2483.62
EBIT Margin
-23.30%-55.55%-45.99%-3.83%10.19%13.21%
Effective Tax Rate
----21.64%3.48%
Revenue as Reported
73.95225.27351.2519.62532.44632.95